一分钟看懂
这是一项关于晚期实体瘤的I 期 / II 期研究，登记的药物或干预包括GI-108，当前状态为招募中。登记地点显示中国Seoul有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
GI-108 · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Yonsei University Health System, Severance Hospital · Seoul
- Asan Medical Center · Seoul
- Samsung Medical Center · Seoul
公开的入选条件
- * Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatoryguidelines) at the time of screening.
- * Has adequate organ and marrow function as defined in protocol.
- * Measurable disease as per RECIST v1.1.
- * ECOG performance status 0-1.
- * Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy,other prior systemic anti-cancer therapy, or surgery must have resolved to Grade≤1, except alopecia and Grade 2 peripheral neuropathy.
- * HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07172802；登记信息更新于 2026-09-17。